Adicet Bio, Inc. (0HX7.L)
USD 0.68
(0.39%)
USD 0.68
(0.39%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 207.29 Million USD | -37.31% |
| 2022 | 330.69 Million USD | -2.43% |
| 2021 | 338.93 Million USD | 120.33% |
| 2020 | 153.83 Million USD | 88.55% |
| 2019 | 81.58 Million USD | -25.79% |
| 2018 | 109.93 Million USD | 99.19% |
| 2017 | 55.19 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 293.09 Million USD | 41.39% |
| 2024 Q2 | 268.84 Million USD | -8.27% |
| 2023 Q3 | 233.25 Million USD | -15.98% |
| 2023 FY | 207.29 Million USD | -37.31% |
| 2023 Q4 | 207.29 Million USD | -11.13% |
| 2023 Q2 | 277.63 Million USD | -8.97% |
| 2023 Q1 | 304.97 Million USD | -7.78% |
| 2022 FY | 330.69 Million USD | -2.43% |
| 2022 Q3 | 354.3 Million USD | 7.4% |
| 2022 Q2 | 329.9 Million USD | -3.1% |
| 2022 Q1 | 340.45 Million USD | 0.45% |
| 2022 Q4 | 330.69 Million USD | -6.66% |
| 2021 Q1 | 282.07 Million USD | 83.36% |
| 2021 FY | 338.93 Million USD | 120.33% |
| 2021 Q2 | 268.77 Million USD | -4.71% |
| 2021 Q4 | 338.93 Million USD | 31.78% |
| 2021 Q3 | 257.19 Million USD | -4.31% |
| 2020 Q4 | 153.83 Million USD | 2.29% |
| 2020 Q3 | 150.39 Million USD | 101.89% |
| 2020 Q2 | 74.49 Million USD | -2.09% |
| 2020 Q1 | 76.08 Million USD | -6.74% |
| 2020 FY | 153.83 Million USD | 88.55% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | 81.58 Million USD | -25.79% |
| 2019 Q4 | 81.58 Million USD | 0.0% |
| 2018 FY | 109.93 Million USD | 99.19% |
| 2017 FY | 55.19 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 75.075% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 77.88% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 73.351% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -25.251% |
| bluebird bio, Inc. | 619.16 Million USD | 66.52% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -64.724% |
| Imunon, Inc. | 21.91 Million USD | -845.772% |
| Editas Medicine, Inc. | 499.15 Million USD | 58.471% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.223% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 93.822% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 82.707% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 93.624% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 85.288% |
| Verastem, Inc. | 149.71 Million USD | -38.457% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.744% |
| Waters Corporation | 4.62 Billion USD | 95.52% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.79% |
| Biogen Inc. | 26.84 Billion USD | 99.228% |
| Nektar Therapeutics | 398.03 Million USD | 47.92% |
| Perrigo Company plc | 10.8 Billion USD | 98.082% |
| Dynavax Technologies Corporation | 997.09 Million USD | 79.21% |
| Illumina, Inc. | 10.11 Billion USD | 97.95% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -633.206% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 73.436% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 6.836% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -215.566% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 96.97% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -25.39% |
| Evolus, Inc. | 188.99 Million USD | -9.681% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -5.01% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.373% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -0.728% |
| FibroGen, Inc. | 423.52 Million USD | 51.055% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 98.074% |
| OPKO Health, Inc. | 2.01 Billion USD | 89.696% |
| Homology Medicines, Inc. | 47.05 Million USD | -340.519% |
| Geron Corporation | 394.07 Million USD | 47.397% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 94.587% |
| Exelixis, Inc. | 2.94 Billion USD | 92.955% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 43.745% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -34.271% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 84.066% |
| Zoetis Inc. | 14.28 Billion USD | 98.549% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 64.76% |
| Abeona Therapeutics Inc. | 64 Million USD | -223.888% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.088% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -270.507% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 93.067% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 93.65% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 66.647% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 88.04% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 80.244% |
| Insmed Incorporated | 1.32 Billion USD | 84.412% |
| TG Therapeutics, Inc. | 329.58 Million USD | 37.105% |
| Incyte Corporation | 6.78 Billion USD | 96.944% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 88.703% |